Inclusion Criteria

• Patient must have a diagnosis of SLE > 6 months according to the 1989 revised ACR criteria. Patient must meet at least four of the eleven ACR criteria for systemic lupus
• Patient must have a modified SLEDAI score > 3 at both screening and qualifying visits (Appendix A-2)
• Patient must be treated for SLE with doses of prednisone < 30 mg/day (including those on NO glucocorticoid therapy) unchanged for > 6 weeks prior to study entry (including both screening and qualifying visits). Prednisone dose in patient's receiving alternate day therapy will be the mean daily prednisone dose
• Patient treated with azathioprine, methotrexate, or hydrochloroquine must be on a stable dose with no change in dose for at least 6 weeks preceding the study
• Patient must be able to read and speak English and willing to sign an informed consent in English

Exclusion Criteria

• Patient with a history of prostate cancer
• Patient with elevated Prostate Specific Antigen (PSA)
• Patient diagnosed with liver disease, defined as AST or ALT > 3x the upper limit of normal
• Patient ingesting body building/anabolic steroids within the last 6 months preceding the study
• Patient with end stage renal disease or receiving hemodialysis treatment
• Patient with serum creatinine > 2 mg/dl or creatinine clearance < 60 ml/min
• Patient receiving treatment with ACTH within the 3 months preceding study entry
• Patient receiving androgens, immunoglobulins, cyclophosphamide, cyclosporin A, or other immunosuppressive agents, except azathioprine, methotrexate, and hydrochloroquine within the last 3 months
• Patient with known hypersensitivity to DHEA or the inactive ingredients used in the GL70l formulation (cornstarch, lactose, and magnesium stearate)
• Patient who participated in any prior DHEA study or administration of DHEA within the past 3 months
• Patient using any investigational agents within the longer of 30 days or 10 half-lives of the agent
• Patient with any condition which in the Investigator's or sponsor's opinion is sufficient to prevent adequate compliance with the study or likely to confuse follow-up evaluation (e.g.. alcoholism, drug addiction, acute withdrawal from chemical dependency, psychiatric disease)
• Patient requires treatment/medication prohibited by protocol
• Patient with any serious EKG abnormality as determined by the Investigator